Search company, investor...

Predict your next investment

CooperCompanies company logo
Corporation
coopercos.com

Partners & Customers

1

Service Providers

1

About CooperCompanies

CooperCompanies is a global medical device company publicly traded on the NYSE Euronext (NYSE: COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has approximately 8,000 employees with products sold in over 100 countries.

Headquarters Location

Pleasanton, California,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest CooperCompanies News

CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)

Feb 15, 2024

CooperCompanies SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol “COO”. The stock split supports Cooper’s desire to make ownership of its stock more accessible to employees and investors. Cooper previously announced on its fourth quarter 2023 earnings release dated December 7, 2023, that it would implement the stock split of its outstanding shares of common stock, as approved by its board of directors. The stock split is a mandatory exchange. The new CUSIP number for Cooper’s common stock following the split will be 216648501. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit  www.coopercos.com . Forward-Looking Statements This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Certain statements including, without limitation, statements regarding the expected timing and impact of the stock split are “forward-looking statements” that are subject to risks and uncertainties. Various important factors could cause results to differ materially, including the risks identified in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such disclosures may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. Contact:

CooperCompanies Acquisitions

9 Acquisitions

CooperCompanies acquired 9 companies. Their latest acquisition was Cook Medical - Reproductive Health Business on February 07, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/7/2022

$99M

Acquired Unit

3

11/11/2021

Subscribe to see more

$99M

Subscribe to see more

10

5/4/2021

Seed / Angel

Subscribe to see more

$99M

$99M

Subscribe to see more

10

3/1/2021

Subscribe to see more

$99M

Subscribe to see more

10

2/3/2021

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/7/2022

11/11/2021

5/4/2021

3/1/2021

2/3/2021

Investment Stage

Seed / Angel

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired Unit

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

CooperCompanies Partners & Customers

1 Partners and customers

CooperCompanies has 1 strategic partners and customers. CooperCompanies recently partnered with BioSkryb on October 10, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

10/18/2022

Licensee

United States

BioSkryb, Cooper ink license deal for genomic technology for women's reproductive health

The Cooper unit Cooper signed an agreement to license BioSkryb ' proprietary genomic amplification technology for use in women 's reproductive health markets .

1

Date

10/18/2022

Type

Licensee

Business Partner

Country

United States

News Snippet

BioSkryb, Cooper ink license deal for genomic technology for women's reproductive health

The Cooper unit Cooper signed an agreement to license BioSkryb ' proprietary genomic amplification technology for use in women 's reproductive health markets .

Sources

1

CooperCompanies Service Providers

1 Service Provider

CooperCompanies has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired Unit

Investment Bank

Sole Financial Advisor

Service Provider

Associated Rounds

Acquired Unit

Provider Type

Investment Bank

Service Type

Sole Financial Advisor

Partnership data by VentureSource

CooperCompanies Team

1 Team Member

CooperCompanies has 1 team member, including current Chief Operating Officer, Executive Vice President, Daniel McBride.

Name

Work History

Title

Status

Daniel McBride

Chief Operating Officer, Executive Vice President

Current

Name

Daniel McBride

Work History

Title

Chief Operating Officer, Executive Vice President

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.